| Announcement | Date |
|---|---|
EMBEDA® AnnouncementAs of November 15, 2019, Pfizer will no longer commercialize EMBEDA® CII (morphine sulfate and naltrexone hydrochloride) extended release capsules. Anticipated unavailability of the product is early 2020. This decision was not made because of any safety or efficacy issues, or because of manufacturing concerns. Patients should talk to their healthcare provider about other appropriate options to help manage their pain. |
October 17, 2019 |
Partner4Better (P4B) Launches!Pfizer Medical Information is pleased to announce the launch of the Partner4Better (P4B) global microsite where healthcare professionals (HCPs) have access to 5 educational modules- Medical Information, Counterfeits, Health Literacy, Medication Adherence and Literature Searching. Click here to access: https://www.partner4better.com/. |
October 10, 2019 |
VYNDAQEL® OR VYNDAMAX™ Dose Conversion ToolThis tool was designed to help with VYNDAQEL® OR VYNDAMAX™ dose conversion. |
September 13, 2019 |
Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)On June 27, 2019, Pfizer received FDA approval for ZIRABEV™ (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab). The FDA approval was based on review of a comprehensive data package which demonstrated biosimilarity of ZIRABEV to the reference product. Please see the full press release via the link below for further details. For medical information, please call Pfizer at 1-800-438-1985 |
July 2, 2019 |